Autoimmune hemolytic anemia medical therapy
|
Autoimmune hemolytic anemia Microchapters |
|
Differentiating Autoimmune hemolytic anemia from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Autoimmune hemolytic anemia medical therapy On the Web |
|
American Roentgen Ray Society Images of Autoimmune hemolytic anemia medical therapy |
|
Directions to Hospitals Treating Autoimmune hemolytic anemia |
|
Risk calculators and risk factors for Autoimmune hemolytic anemia medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Assosciate Editor(s)-In-Chief: Prashanth Saddala M.B.B.S
Please help WikiDoc by adding more content here. It's easy! Click here to learn about editing.
Overview
Medical Therapy
Much literature exists regarding the treatment of AIHA. Efficacy of treatment depends on the correct diagnosis of either warm or cold type AIHA.
The aim of therapy may sometimes be to lower the use of steroids in the control of the disease. In this case, splenectomy may be considered, as well as other immunosuppressive drugs. Infection is a serious concern in patients on long-term immunosuppressant therapy, especially in very young children (less than two years).[1]
Warm type AIHA is usually a more insidious disease, not treatable by simply removing the underlying cause. First line therapy for this is usually with corticosteroids, such as prednisolone. Following this, other immunosuppressants are considered, such as rituximab, danazol, cyclophosphamide, azathioprine or cyclosporine.
Cold agglutinin disease is treated by avoiding the cold or sometimes with rituximab. Removal of the underlying cause is also important.
Paroxysmal cold hematuria is treated by removing the underlying cause, such as infection.
References
- ↑ Zecca M, Nobili B, Ramenghi U; et al. (2003). "Rituximab for the treatment of refractory autoimmune hemolytic anemia in children". Blood. 101 (10): 3857–61. doi:10.1182/blood-2002-11-3547. PMID 12531800. Unknown parameter
|month=ignored (help)